MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway
Authors: F-L Yuan
R Zheng
M Li
Journal: European review for medical and pharmacological sciences (2018)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: JAK-STAT pathway; SOCS3; miR-410; NSCLC; apoptosis
Affiliations: Department of Respiration, Yantai Yeda Hospital, Yantai, Shandong, China. .

Abstract:  Objective: Janus kinase (JAK) - signal transducer and activator of transcription (STAT) signal pathway participates in regulating cell proliferation, differentiation, and apoptosis, and is correlated with non-small cell lung cancer (NSCLC) onset. Suppressors of cytokine signaling 3 (SOCS3) negatively regulates JAK-STAT pathway. SOCS3 is down-regulated in NSCLC tissues, with an elevation of miR-410 expression. This study thus intends to investigate if miR-410 plays a role in mediating NSCLC onset and underlying mechanism in this regulatory process. Patients and methods: NSCLC patients were collected for tumor and adjacent tissues, among which, miR-410 and SOCS3 expression were measured. Dual luciferase reporter gene assay was employed to confirm the targeting relationship between miR-410 and SOCS3. Their expression levels were compared between A549 and BEAS-2B cells. Cultured A549 cells were treated with anti-miR-410 and/or SOCS3. Expression levels of SOCS3, p-JAK1/2, p-STAT3, and Bcl-2 were compared along with the apoptotic rate of cells. Results: Bioinformatics analysis revealed targeted binding site between miR-410 and 3'-UTR of SOCS3 mRNA. Compared to those in tumor tissues, a significant increase of miR-410 and reduction of SOCS3 were found in NSCLC tissue (p &lt; 0.05). Dual luciferase reporter gene assay indicated that SOCS3 was targeted regulated by miR-410. Significantly higher miR-410 and lower SOCS3 levels were shown in A549 cells, compared to those in BEAS-2B cells. Transfection of anti-miR-410 and/or SOCS3 in A549 cells, SOCS3 expression and apoptosis were significantly induced, while JAK1, JAK2, and STAT3 phosphorylation were statistically decreased with the reduction of the Bcl-2 level (p &lt; 0.05). Conclusions: miR-410 level was increased while SOCS3 expression was declined in NSCLS tissues. MiR-410 induces the apoptosis of A549 cells through downregulating JAK/STAT3/SOCS3 signaling pathway, which provides new insights for the therapy of pulmonary carcinoma in clinic. 

Retracted: Yes

PubPeer comments:
 A Gallery of Unfortunate FACS Plots. Please excuse the length. This is a random assortment from a certain oeuvre. Any other of ~40 papers from the same journal(s) could have been used instead. I have only marked a few of the recurring constellations of points. Colored plots darkened and contrast-enhanced for visibility. Fig 4C [Liu et al (2017)] PMID 28770966 Fig 2D, 3D [Wu et al (2017)] PMID 28617558 Fig 2D [Liang et al (2017)] PMID 29164556  Fig 3E [Li et al (2018)] 10.26355 eurrev_201809_15933 Fig 4D [Dong et al (2018)] 10.26355 eurrev_201805_15059 Fig 4D [Song et al (2018)] 10.26355 eurrev_201806_15153  Fig 2B, 4B, 5C [Wang et al (2018)] 10.26355 eurrev_201801_14201 Fig 3B, 4E [Su Song (2018)] 10.26355 eurrev_201810_16155 Fig 2D [Han et al (2018)] 10.26355 eurrev_201811_16390  Fig 4C [Wang Yu (2019)] 10.26355 eurrev_201903_17397 Fig 5D [Zhou et al (2019)] 10.26355 eurrev_201911_19436 Fig 4E [Liu Zhang (2019)] 10.1089 cbr.2018.2749 Fig 4D [Piao et al (2019)] 10.1089 cbr.2018.2625  , 
 It may also be worth documenting the curious stylized renditions of Western Blots favoured by this production studio (and by the editors and reviewers who accept this oeuvre of papers).  , 
 Withdrawn. https: www.europeanreview.org article 23747 *Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, u201cMiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3 JAK-STAT signaling pathway, by M. Li, R. Zheng, F.-L. Yuan, published in Eur Rev Med Pharmacol Sci 2018; 22 (18): 5987-5993u2013DOI: 10.26355 eurrev_201809_15933u2013PMID: 30280781u201d has been withdrawn.* *The Publisher apologizes for any inconvenience this may cause.* ,